Titre (en)
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration sur la maladie de Parkinson - Exploration (Accueil)

Index « Titre (en) » - entrée « selegiline »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
seledo < selegiline < selenium  Facettes :

List of bibliographic references indexed by selegiline

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]
Ident.Authors (with country if any)Title
000F56 (2007) V. Pursiainen [Finlande] ; T. J. Korpelainen [Finlande] ; H. T. Haapaniemi [Finlande] ; A. K. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande]Selegiline and blood pressure in patients with Parkinson's disease
001557 (2004) Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
001885 (2002) Ira Shoulson [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Anthony Lang ; J. William Langston [États-Unis] ; Peter Lewitt [États-Unis] ; C. Warren Olanow [États-Unis] ; John B. Penney ; Caroline Tanner [États-Unis] ; Karl Kieburtz [États-Unis] ; Alice Rudolph [États-Unis]Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
001C34 (2000) J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; A. Gordin [Finlande] ; E.-R Kultalahti [Finlande] ; H. Ter V Inen [Finlande]Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study
001D39 (1999) H. Przuntek ; B. Conrad [Allemagne] ; J. Dichgans ; P. H. Kraus ; P. Krauseneck ; G. Pergande ; U. Rinne [Finlande] ; K. Schimrigk ; J. Schnitker ; H. P. Vogel [Allemagne]SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa
001F81 (1997) LeWitt [États-Unis] ; David Oakes [États-Unis] ; Lu Cui [États-Unis]The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol
001F84 (1997) Larsen [Norvège] ; Jette Boas [Danemark]The effects of early selegiline therapy on long‐term levodopa treatment and parkinsonian disability: An interim analysis of a norwegian–danish 5‐year study
001F92 (1997) V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande]Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
002126 (1996) C. Kirollos ; A. Charlett ; S. G. Bowes ; A. G. Purkiss ; C. J. A. O Eill ; C. Weller ; J. Dickins ; G. Faulkner ; P. W. Nicholson ; W. B. Hunt ; R. J. Dobbs ; S. M. DobbsTime course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonism
002159 (1996) T. Salonen ; Antti Haapalinna ; Esa Heinonen ; Jaana Suhonen [États-Unis] ; Antti HervonenMonoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity
002284 (1995) J. Knoll [Hongrie]Rationale for (−)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes
002454 (1994) Letizia Mazzini [Italie] ; Daniela Testa [Italie] ; Carla Balzarini [Italie] ; Gabriele Mora [Italie]An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis
002549 (1993) H. Heinonen [Finlande] ; M. Savij Rvi [Finlande] ; M. Kotila [Finlande] ; A. Hajba [Finlande] ; M. Scheinin [Finlande]Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
002613 (1992) K. Wessel [Allemagne] ; I. SzelenyiSelegiline — An overview of its role in the treatment of Parkinson's disease
002682 (1991) H. Allain [France] ; J. Cougnard [France] ; H-C. Neukirch [France]Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT)
002703 (1991) A. Lieberman [États-Unis] ; E. Fazzini [États-Unis]Experience with selegiline and levodopa in advanced Parkinson's disease
002725 (1991) E. H. Heinonen [Finlande] ; R. Lammintausta [Finlande]A review of the pharmacology of selegiline
002823 (1989) Heinonen E. H [Finlande] ; Rinne U. K [Finlande]Selegiline in the treatment of Parkinson's disease
002826 (1989) Heinonen E. H [Finlande] ; Myllyl V ; Sotaniemi K ; Lammintausta R [Finlande] ; Salonen J. S [Finlande] ; Anttila M [Finlande] ; Savij Rvi M ; Kotila M ; Rinne U. K [Finlande]Pharmacokinetics and metabolism of selegiline
002A73 (1983) Melvin D. Yahr [États-Unis] ; Marina R. Mendoza [États-Unis] ; Daniel Moros [États-Unis] ; Kenneth J. Bergmann [États-Unis]Treatment of Parkinson's disease in early and late phases. Use of pharmacological agents with special reference to deprenyl (selegiline)
002A84 (1983) P. Riederer [Autriche] ; K. Jellinger [Autriche]Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "selegiline" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "selegiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    selegiline
}}
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024